$460m pledged for vaccine initiative aimed at preventing global epidemics

Lassa, Mers and Nipah will be first diseases targeted by programme announced at Davos by coalition of governments, philanthropists and business

A coalition of governments, philanthropists and business is pledging to put money and effort into making vaccines to stop the spread of diseases that could threaten mankind – and to prevent another outbreak as devastating as the Ebola epidemic.

At the World Economic Forum in Davos, the Norwegian, Japanese and German governments, the Wellcome Trust and the Gates Foundation announced they were putting in $460 million – half of what is needed for the first five years of the initiative. Three diseases will initially be targeted: Lassa, Mers and Nipah. All three are caused by viruses that have come from animals to infect humans and could trigger dangerous global epidemics.

Ebola virus had been known since it first infected humans in 1976, but the outbreaks were relatively small and, although deadly, did not greatly trouble most of the world until the disease hit cities, spread across west Africa and cases were seen in the USA and Europe.

Experts are determined to do everything they can to prevent such unexpected disasters. Ebola killed more than 11,000 people and devastated the healthcare systems and economies of Sierra Leone, Guinea and Liberia.

The Coalition for Epidemic Preparedness Innovations (CEPI) will direct money into research for vaccines for infectious diseases that afflict low and middle-income countries and are not research priorities for pharmaceutical companies because there is not a lucrative market for them. One of the key aims of CEPI will be to ensure the vaccines are affordable and accessible to all who need them.

Jeremy Farrar, chief executive of the Wellcome Trust, said changes in the environment, in people’s interactions with animals and urbanisation were all factors that could trigger an outbreak in humans of a new infectious disease. Of the series of epidemics in the last couple of decades he said: “That is not going to stop. It is the way the world is structured now.”

There had been a tendency, though, to forget about the dangers once an outbreak has ended, noted Farrar. “Sars is the best example. The epidemic faded away and then interest went on to other things,” he said.

Ebola was different, said Farrar. “It was on TV screens and many people witnessed it for themselves. There was a feeling that this can never happen again. It was horrific. Many thousands of lives were lost. But also there was the optimism and hope that maybe for the first time in history, a vaccine was found to be safe and effective. We can dare to dream and can change the way things happen.”

CEPI aims to develop two promising vaccines against each of the first three diseases so that they are available before any epidemic breaks out.

Sir Andrew Witty, chief executive of GlaxoSmithKline (GSK), which is involved in the initiative, said: “We are not really learning the lessons from the previous pandemic. We are never really changing our level of readiness.” GSK was asked by the World Health Organisation in the summer of 2014 to try to develop an Ebola vaccine and had it ready to trial by the following January. That time could have been much shorter if there had been something on the shelf.

The company intends to create a “biopreparedness organisation”, based permanently at its research facility in Rockville in the USA, to work on a no-profit, no-loss basis to develop vaccines for diseases that could potentially pose public health threats.

Epidemics, said Erna Solberg, prime minister of Norway, “ ... can ruin societies on a scale only matched by wars and natural disasters. They respect no borders and don’t care if we are rich or poor. Protecting the vulnerable is protecting ourselves. This is why we all must work together to be better prepared – and why my government is fully committed to ensure that CEPI achieves its mission.”


Sarah Boseley Health editor

The GuardianTramp

Related Content

Article image
Researchers make strides in race to create coronavirus vaccine
International teams accelerate efforts to find effective immunisation method

Peter Beaumont

01, Feb, 2020 @8:00 AM

Article image
Hopes UK trial will allay pregnant women’s Covid vaccine concerns
Researchers aim to determine optimal gap between doses as well as explore potential side-effects in more detail

Nicola Davis Science correspondent

03, Aug, 2021 @5:01 AM

Article image
‘They thought Covid only kills white people’: myths and fear hinder jabs in DRC
Mutant strain may emerge amid vaccine hesitancy, experts say, as even medics reject jabs in DR Congo

Lisa Murray in Kinshasa

05, Aug, 2021 @6:00 AM

Article image
Oxford AstraZeneca vaccine to be sold to developing countries at cost price
Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’

Peter Beaumont

23, Nov, 2020 @4:14 PM

Article image
Malaria vaccine could save millions of children's lives

Researchers 'on the cusp' of a vaccine after widescale African trial shows the risk of malaria cut in half

Sarah Boseley, health editor

18, Oct, 2011 @6:31 PM

Article image
‘We haven’t finished the job’: JVT reflects on 18 months of Covid
Exclusive: Listen to the experts, says deputy chief medical officer Jonathan Van-Tam, not the celebrities

Nicola Davis Science correspondent

24, Sep, 2021 @10:32 AM

Article image
WHO endorses use of world’s first malaria vaccine in Africa
World Health Organization’s director general hails ‘historic day’ in fight against parasitic disease

Lizzy Davies

06, Oct, 2021 @5:17 PM

Article image
'We need to talk about shit': six bugs cause 78% of diarrhoea cases
Pathogens are to blame for twice as many cases as thought, study finds, paving way for more effective vaccines and antibiotics

Nicola Davis

22, Sep, 2016 @10:30 PM

Article image
Pfizer Covid vaccine: what has the trial found and is this a breakthrough?
Early results from phase 3 trial look promising but there are still many questions to be answered

Nicola Davis Science correspondent

10, Nov, 2020 @8:23 AM

Article image
Hope, horror and Covid-19: my 23 years as the Guardian’s health correspondent | Sarah Boseley
I’ve travelled the world covering everything from HIV to MMR to Ebola… and then Covid came along. These are stories that changed me – and the world

Sarah Boseley

17, Jul, 2021 @11:00 AM